Objective: Evaluate the safety and efficacy of OBV/PTV/r + DSV with low-dose RBV (600 mg once daily) for 12 weeks in GT1a HCV-infected patients, naïve or experienced (with pegIFN/RBV), without cirrhosis and compare with the historical SVR12 rate for 3-DAA + full-dose, weight based RBV as determined by the phase 3 PEARL-IV study.
